Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olodaterol/tiotropium bromide - Boehringer Ingelheim

Drug Profile

Olodaterol/tiotropium bromide - Boehringer Ingelheim

Alternative Names: BI-1744-CL/tiotropium bromide; Spiolto Respimat; Stiolto; STIOLTO RESPIMAT; Tiotropium bromide/BI-1744-CL; Tiotropium bromide/olodaterol; Vahelva Respimat

Latest Information Update: 21 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Amines; Benzoxazines; Bronchodilators; Epoxy compounds; Esters; Ketones; Small molecules; Thiophenes; Tropanes
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 08 Sep 2021 Launched for Chronic obstructive pulmonary disease in France, Greece, Hungary, Portugal, Belgium, New Zealand, Israel, Germany, Sweden, Poland, Chile, Russia, Philippines, Netherlands, Czech Republic, Indonesia, Hong Kong, Argentina, Switzerland, Turkey, Mexico, Singapore, Ukraine (Inhalation) before September 2021
  • 08 Sep 2021 No development reported - Phase-III for Chronic obstructive pulmonary disease in Guatemala, Colombia, South Africa, Malaysia, Serbia, Taiwan, Brazil, India, Peru, Vietnam, Thailand (Inhalation)
  • 17 May 2019 Updated efficacy data from the phase III DYNAGITO trial in Chronic obstructive pulmonary disease presented at the 115th International Conference of the American Thoracic Society (ATS-2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top